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Abstract 
Introduction  Among women, breast cancer is the most prevalent cancer 
and the second leading cause of cancer death.  Although technology advances 
have improved survival rates for breast cancer overall, improvements have not 
been universally experienced by all socioeconomic and racial groups.  Known 
determinants of breast cancer care disparities include socioeconomic status, 
race, age, and social support.  As a part of the Breast and Cervical Cancer 
Mortality Prevention Act of 1990 and with the help of CDC funding, the Virginia 
Breast and Cervical Cancer Early Detection Program (BCCEDP) or Every 
Woman’s Life (EWL) was created.  EWL provides breast cancer screening to 
female VA residents between the ages of 18 and 64 who lack health insurance 
and fall at or below 200% of the Federal Poverty Level. 
Objective The purpose of this study is to determine if delays in the diagnosis 
and treatment of breast cancer, within the VDH program EWL, differs based on 
sociodemographic characteristics and/ or regional location. 
Methods From its inception to July 2008, 705 women received a breast 
cancer diagnosis through the EWL program.  For these 705 cases prevalence 
and crude odds ratios were calculated for both diagnosis and treatment delays 
for all of the demographic variables along with 95% confidence intervals.  
Adjusted odds ratios were calculated for sociodemographic variables against 
screening to diagnosis delays and diagnosis to treatment disparities along with 
95% confidence intervals. 
Results According to the crude odds ratios more women who fall into the 
other category of race experienced diagnosis delays (OR=2.28 [1.11, 4.67]), but 
they were more likely to receive treatment in a timely manner (OR=0.29 [0.11, 
0.79]).  Women living alone were also more likely to experience diagnosis delays 
(OR=1.49 [1.10, 3.02]). Hispanic women were more likely to receive treatment in 
a more timely manner than non-Hispanic women (OR=0.21 [0.05, 0.81]).  Also, 
women being treated in any other region than northern VA were more likely to 
experience treatment delays.  However, according to the adjusted odds ratios, 
the only significant timing delay was the one experienced more often by women 
in the other race category. 
Conclusion The research indicates known indicators of disparities within cancer 
care as socioeconomic status, race, ethnicity, age, and social support.  The 
findings of this study indicate that the only significant indicator of disparity within 
the Every Women’s Life program is race.  Although, African-American women 
were just as likely to receive timely diagnosis and treatment as white women in 
the program, it was the combined groups of Asian, American Indian, and other 
women that were more likely to experience diagnosis, but not treatment, delays.  
The fact that no other significant indicators of disparities were found within EWL 
indicates a success of the program, as EWL is targeting those women that would 
have otherwise been missed by the system. 
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Introduction 
Cancer is the second leading cause of death for women in the United 
States following coronary heart disease1.  The most common cancer affecting 
women is breast cancer.  After lung cancer, breast cancer causes more death 
than any other cancer2.  In 2008, among females, there were an estimated 
184,450 newly diagnosed cases and 40,480 deaths due to breast cancer in the 
United States3.  Cancer care begins with risk assessment and primary 
prevention, followed by screening, detection, and diagnosis.  Treatment, 
recurrence, surveillance, and end-of-life care are also very important facets of 
cancer care. Although technology advances have improved survival rates for 
breast cancer overall, improvements have not been universally experienced by 
all socioeconomic and racial groups. Timely access to all parts of the cancer care 
continuum needs to be improved in order to eliminate cancer care disparities4. 
  Insuring that all women receive early breast cancer screening is 
particularly important because cancer is most treatable at the early stages3.  The 
American Cancer Society publishes early detection guidelines for breast cancer 
based on the current scientific research.  These include a yearly mammogram 
starting at age 40.  However, not everyone has health insurance; therefore, they 
are unable to afford a yearly mammogram.  Detecting breast cancer at early 
stages leads to both decreased morbidity and mortality5. 
Socioeconomic status has a well known association with health care 
disparities, and cancer is no exception; however, racism, exposure to stress, 
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acculturation, resources, geographic location, and medical care are all 
contributing factors1.   However, not all research agrees on the most influential 
determinant of health disparities, more specifically cancer care disparities; 
although, it has been proposed that disparities are more often based on income 
level than either education or race1,6,7.  Other research has identified 
determinants such as geographic location, as a key contributor to cancer care 
disparities8,9.  Jacobs found that rural patients have an increased probability of 
mastectomy8.  Lund discussed the prevalence of disparities within urban cancer 
care settings9.  However, Mobley discusses the probability that geographic 
location is not a determinant of cancer care disparities because the variations 
have been falsely interpreted because variations fluctuate more across a 
geographic region than within one10.   
Past research has identified that black women were significantly more 
likely to receive a diagnosis of breast cancer at an advanced stage of the disease 
than were their white women peers11,12,13,14.  African American women also have 
lower breast cancer survival rates than white women; 5 year survival rates from 
1981 to 1995 for white and African American women were 86% and 71%, 
respectively1,15. Peek16 discussed the possibility that African-American women, 
who have the highest rates of breast cancer death, avoid screening for breast 
cancer.  Possible reasons include a fear of the health care system, psychosocial 
issues, fatalism, denial and repression, a previous negative experience with the 
health care system, perceived discrimination, and poor health outcomes16,17.  
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Other research has identified racial discrimination as an important factor; women 
with perceived discrimination were less likely to get cancer screening2,17.  Social 
support can be a factor in seeking cancer care because family members provide 
a network that helps one overcome fears18.  Having social support can affect the 
quality of life of the women receiving cancer diagnoses and treatment.  There is 
also evidence that age plays a factor in receiving timely breast cancer 
screening19.  Although women over 65 represent around 44% of newly diagnosed 
breast cancer cases and 56% of breast cancer deaths, only around 66% of 
women over age 70 are being screened according to guidelines.  When these 
women receive a breast cancer diagnosis, it is more likely to be at a later stage. 
Nationally and locally, there has been an influx of programs developed to 
address this problem since 1990.  In 1990, the Breast and Cervical Cancer 
Mortality Prevention Act was signed into law.  Due to this law, the Centers for 
Disease Control and Prevention (CDC) was charged with the task of creating a 
national program to improve access to breast and cervical cancer screening20.  
As a part of this national initiative, with the help of CDC funding, the Virginia 
Breast and Cervical Cancer Early Detection Program (BCCEDP) or Every 
Woman’s Life (EWL) was created.   
Every Woman’s Life is dedicated to providing breast and cervical cancer 
screening to female Virginia residents, between the ages of 40 and 64, who 
might otherwise receive none and ultimately get passed over by the entire 
system.  In 2006, EWL routine screening was restricted to women ages 45-64 
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but expanded to symptomatic women between the ages of 18 and 44 years.  
Eligibility criteria for EWL also includes Virginia residency, lack of health 
insurance, and an income at or below 200% of the Federal Poverty Level21.  In 
order for Every Woman’s Life to reach all the women who need its services 
throughout the state, there are dozens of screening sites throughout the state22. 
The purpose of this study is to determine if delays in the diagnosis and 
treatment of breast cancer, within the VDH program EWL, differs based on 
sociodemographic characteristics and/ or regional location. Specifically the 
current study will: 
1) Quantify the prevalence of screening to diagnosis and diagnosis to 
treatment delays among women in Virginia’s EWL program 
2) Identify sociodemographic and/or regional disparities in timely diagnosis 
and treatment following an abnormal screening result in these women. 
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Methods 
Through the Breast and Cervical Cancer Mortality Prevention Act of 1990, 
the CDC has set up clinical guidelines which help to eliminate any cancer care 
disparities.  The guidelines from CDC mandate that that at least 75% of the 
women receiving screening through programs such as EWL should have a 
diagnosis within 60 days of screening and for at least 80%, treatment should start 
at least 60 days after diagnosis.  EWL is administered by the Virginia Department 
of Health (VDH); however, it is up to local health providers to carry out the 
screening.  The goal is to eliminate any disparities that might exist at any time 
during the cancer care continuum.   
An analysis was conducted on the data set collected by the Virginia 
Department of Health program Every Woman’s Life between September 1997 
and July 2008.  Women who received free cancer screening from Every 
Woman’s Life had to meet certain criteria.  Women who were between the ages 
of 40 and 64, residents of Virginia, lacking insurance coverage, or unable to pay 
the deductible, at 200% or below the Federal Poverty Level have been covered 
by Every Woman’s Life since the program’s inception21.  Beginning in July of 
2006, Every Woman’s Life screening for breast and cervical cancer became 
available to symptomatic women between the ages of 18 and 49. 
This data set used in the current study included all women that were 
provided breast cancer screening through the program Every Woman’s Life.  
Data collection for each member of the retrospective cohort began at enrollment 
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in the program and continued through either the initiation of treatment or a 
negative screening result.  There were 40,845 screening mammograms 
performed between September 1997 and July 2008. This included 705 women 
with a breast cancer diagnosis.  The information collected included date of birth, 
Every Woman’s Life provider, residential county, race, ethnicity, primary 
language, household income, household occupancy, federal poverty level, breast 
cancer history, screening date, diagnosis date, treatment date, and final 
diagnosis. 
Statistical Analyses 
 The outcomes of interest were the intervals from screening to diagnosis 
and diagnosis to treatment.  These variables were calculated as number of days 
between the events.  In preliminary analyses, it was found that within the EWL 
program, 87.4% of women diagnosed with breast cancer received their diagnosis 
before the CDC standard, 60 days, and 92.1% of them started treatment within 
60 days from diagnosis as well.  EWL successfully meets CDC minimum 
standards, but there might still be room for improvement. Diagnosis and 
treatment should occur as soon as possible, so the time interval of interest was 
narrowed to look for areas in need of improvement within EWL.  In these 
analyses, screening to diagnosis and diagnosis to treatment delays were defined 
as any case where the time interval was greater than 30 days.    Other variables 
of interest were race, income, age, and region of residence within Virginia, and 
final diagnosis.   
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 SAS 9.1.3 was used for all of the statistical analyses.  Prevalence of 
screening to diagnosis disparities and diagnosis to treatment disparities were 
calculated for each variable as an initial approach for determining what was 
associated with the disparities.  A 95% confidence interval was calculated for 
each prevalence.  The crude odds ratios were then calculated for each category 
as an estimate of risk.  Crude odds ratios were calculated with given references 
and each variable was separate and independent of all other variables.  95% 
confidence intervals were calculated for the crude odds ratio. 
 To account for confounding, adjusted odds ratios were calculated for all 
the demographic variables against screening to diagnosis delays and diagnosis 
to treatment delays along with 95% confidence intervals.  The adjustment 
accounted for Virginia region of residence, race, ethnicity, household income, 
household occupancy, final diagnosis, and age at screening. 
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Results 
 Table 1 illustrates the characteristics of interest for the study participants.  
The majority of the women diagnosed with breast cancer through Every 
Woman’s Life were white (57.3%; black = 36.3%; Asian = 2.7%), non-Hispanic 
(95.3%), and over age 50 (65.5%; 40-50 = 31.8%; under 40 = 2.7%).  The 
regional breakdown of the women was: Northern VA = 5.4%, Northwestern VA = 
16%, Central VA = 7.2%, Eastern VA = 36.9%, and Southwestern VA = 31.8%.  
More than half of the women came from households making between $5,000 and 
$20,000 annually and lived at about 100% of the federal poverty limit.  A little 
under half (46.2%) of the women live alone.  Over 95% of the women have no 
history of a breast cancer diagnosis, and the final diagnosis for over 70% of the 
women was invasive breast cancer, as opposed to Ductal Carcinoma In Situ 
(DCIS) or Lobular Carcinoma In Situ (LCIS).  Women were diagnosed at Stage II 
more often (32.1%; Stage I = 18.0%, Stage III = 16.3%, Stage IV = 6.4%).   
In this analysis, the definition for a normal time interval between diagnosis 
after screening, and receiving treatment after diagnosis was 30 days.  Of the 
women diagnosed with breast cancer, 60.4% of them received their diagnosis at 
least 30 days after screening, and 68.8% of them began treatment at least 30 
days after diagnosis. 
Prevalence 
The prevalence of screening to diagnosis delays and diagnosis to 
treatment delays, stratified within each of the categories, is shown in Table 2.  
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The prevalence of diagnosis delays was highest in the Northern Virginia region 
among women living in households with incomes between $1000 and $5000 and 
no other occupants.  Although delays in diagnosis were more prevalent for 
American Indian women and Hispanic women, there were too few of them for 
statistical significance.  Women diagnosed with DCIS also experienced more 
diagnosis delays than women diagnosed with invasive breast cancer or LCIS.  
This is also true of women with Stage I tumors.   
The prevalence of treatment delays was highest within the Northwestern 
region of Virginia and also for black women.  Women from households of most 
income levels experienced approximately the same level of treatment delays, 
and women living alone and/or under the federal poverty limit did not experience 
a higher prevalence of treatment delays.   The prevalence of treatment delays 
was highest among women below age 40 and those who had no history of breast 
cancer.  There was a higher prevalence of treatment delays experienced by 
women receiving a final diagnosis of invasive breast cancer and/or have a stage 
II tumor. 
Crude Odds Ratio 
To estimate those at greatest risk for experiencing screening to diagnosis 
(see table 3) and diagnosis to treatment delays (see table 4), odds ratios were 
calculated within each category for both variables.  Race did affect the likelihood 
of diagnosis delays, women falling into the other category were 128% more likely 
to experience a diagnosis delay than White women (OR=2.28 [1.11, 4.67]).  
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Women living alone experienced a 49% increase in the odds of a diagnosis delay 
than those living with others (OR=1.49 [1.10, 3.02]).  Women receiving a final 
diagnosis of either invasive breast cancer (OR=0.37 [0.25, 0.54]) or LCIS 
(OR=0.24 [0.08, 0.77]) experienced significantly less diagnosis delays than 
women receiving a DCIS final diagnosis.  Women with tumors at stage III 
(OR=0.39 [0.22, 0.67]) and stage IV (OR=0.28 [0.12, 0.62]) also had decreased 
odds of experiencing diagnosis delays.  
Breast Cancer diagnosis to treatment delays were less likely to be 
experienced by both women in the other category of race when compared to 
White women (OR=0.29 [0.11, 0.79]) and women of Hispanic origin when 
compared to Non-Hispanic origin (OR=0.21 [0.05, 0.81]).   As compared to the 
women treated in the Northern Virginia region, women from all other regions, 
including the Northwestern (OR=3.77 [1.42, 10.00]), Southwestern (OR=2.95 
[1.15, 7.55]), Central (OR=3.85 [1.33, 11.14]), and Eastern (OR= 2.78[1.09, 
7.08]) regions had an increased odds of experiencing treatment delays of greater 
than 30 days.     
 
Adjusted Odds Ratio  
 The adjusted odds ratios for diagnosis delays can be found in table 5 and 
those for treatment delays can be found in table 6.  The adjusted odds ratios 
were calculated to account for all the stratifications presented in the data set.  
When accounting for region, race, ethnicity, age, income, household occupancy, 
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final diagnosis, and treatment delays, there was one statistically significant 
disparity in diagnosis timing.  Women of other races than White and Black who 
sought out screening through Every Woman’s Life were more likely to experience 
diagnosis delays (Adjusted OR=2.52 [1.03, 6.17]).  However, a diagnosis of 
either invasive breast cancer (Adjusted OR=0.40 [0.27, 0.59]) or LCIS (Adjusted 
OR=0.24 [0.07, 0.81]) were protective against diagnosis delays.  However, there 
were no statistically significant treatment delays in the adjusted model.   
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Discussion & Conclusion 
The purpose of this study was to determine if screening, diagnosis, and 
treatment of breast cancer, within the Virginia Department of Health program, 
Every Woman’s Life, differs based on sociodemographic characteristics and/ or 
regional location.  The findings of this study will help improve the delivery of the 
program Every Woman’s Life.  Now that certain risk factors are known for those 
diagnosis and treatment delays, the provider locations can target and improve 
delivery across all of the EWL patients. 
In preliminary analyses, it was found that EWL successfully met CDC’s 60 
day diagnosis and treatment standard.  Over 75% of all women who had 
abnormal screening results received a diagnosis within 60 days and over 80% of 
all women who received a diagnosis also received timely treatment.  No 
detectable disparities existed using the 60 day cutoff within Every Woman’s Life.  
Women were just as likely to receive a timely diagnosis and timely treatment 
regardless of sociodemographic characteristics, and geographic location.   
In order to determine if any improvements could be made within the Every 
Woman’s Life program, the analysis was changed to reflect a shorter 
“acceptable” interval between screening and diagnosis, and diagnosis and 
treatment.  A few disparities were found when this analysis was performed.  In 
the crude analyses it was found that women in the other race category were 
more likely than white women to experience diagnosis delays of greater than 
thirty days and women living alone were more likely to experience diagnosis 
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delays than women living with others.  Also, women from northwestern Virginia, 
southwestern Virginia, and central Virginia were more likely than women from 
northern Virginia to experience treatment delays of greater than thirty days.  This 
might be an indicator that EWL providers in northern Virginia have found a more 
effective, efficient, and timely way to deliver the program.  Although the other 
regions are delivering the program effectively within the acceptable 60 day time 
limit, they might be able to learn from northern Virginia’s success.  In the 
adjusted model only women in the other race category experienced statistically 
significant diagnosis delays and there were no statistically significant treatment 
delays within the EWL program.   
The findings of this study indicate that the only significant indicator of 
disparity within the Every Women’s Life program is race.  Although, African-
American women were just as likely to receive timely diagnosis and treatment as 
white women in the program, it was the combined groups of Asian, American 
Indian, and other women that were more likely to experience diagnosis, but not 
treatment, delays.  Previous studies have identified known indicators of 
disparities within cancer care as socioeconomic status, race, ethnicity, age, and 
social support6,7,11-19; however, this study uses a unique sample of women.  All 
the women included in this study were targeted because of their inability to afford 
breast cancer screening.  Therefore, this selection bias influenced the outcome 
of the study because the women included might not represent their entire 
demographic.  The fact that no other significant indicators of disparities were 
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found within EWL indicates a success of the program, as EWL is targeting those 
women that would have otherwise been missed by the system. 
This retrospective cohort provides a unique look at several steps in the 
cancer care continuum, including breast cancer diagnosis, and treatment 
initiation. However, there were some limitations.  First, women below age 40 
were not eligible for EWL until 2006, so the data might look different if they had 
been included from the start.  Second, the results of this study might be subject 
to differential surveillance bias.  Because women younger than 40 must be 
symptomatic to receive the services offered by Every Woman’s Life, they are less 
likely to be referred to the program and diagnosed at an early stage. Finally, the 
program is targeted to a very specific population within Virginians and therefore 
might not be generalizable to other states or other programs. 
Greater statistical power and more generalizable results could come from 
an analysis of data from the entire country.  Since Virginia’s Every Woman’s Life 
is only one of 63 programs nationwide that delivers this service with the aid of the 
Centers for Disease Control and Prevention, perhaps it would be possible to 
conduct a national evaluation.  Another possible improvement would be to 
increase statewide awareness of the program so that more people could benefit 
from its services.  If this were possible, the women reached by this program 
might start to more accurately reflect the state demographics, and findings could 
be more universally applicable.  Every Women’s Life is successfully helping 
women participating in the program receive both timely diagnosis of breast 
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cancer and treatment regardless sociodemographic characteristics.  If they were 
to try and improve the program, they could make sure that the women in the 
other race category are diagnosed just as fast as white and African-American 
women.  Also, the other regions of the state could learn from Northern Virginia’s 
quick treatment timelines and deliver treatment quicker to their patients as well. 
In order to eliminate health disparities, especially those experienced 
during cancer care such as screening access, diagnosis delays, and treatment 
delays, the approach must be broad.  The entire public health perspective has to 
be addressed, and all determinants of health, such as: access, human behavior, 
environment, and genetics, need to be taken into account23,24.  This includes not 
only behaviors and access to care, but also, the physical and social 
environments, school age exposure to physical education, and restricting toxic 
substance exposure.   
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Tables 
Table 1. Screening to Diagnosis & Diagnosis to Treatment Delays 
  Total sx - dx dx - tx 
Variable (N) % 
delay 
% 
no 
delay 
% 
delay 
% 
no 
delay 
% 
Region 
Northwestern 113 16.0 13.4 17.8 18.7 14.8 
Northern 38 5.4 6.5 4.7 1.9 7.0 
Southwestern 224 31.8 31.2 32.4 31.3 32.0 
Central 51 7.2 7.6 7.0 8.4 6.8 
Eastern 260 36.9 40.6 34.0 35.0 37.5 
unknown 19 2.7 0.7 4.0 4.7 1.9 
Race 
White 404 57.3 54.3 59.6 59.3 56.5 
Black 256 36.3 37.0 35.4 38.3 35.5 
Asian 19 2.7 4.0 1.9 1.9 2.9 
American Indian 3 0.4 0.7 0.2 0.0 0.6 
Other 11 1.6 2.2 1.2 0.0 2.3 
Unknown 12 1.7 1.8 1.6 0.5 2.3 
Ethnicity 
Hispanic origin 20 2.8 3.6 2.3 0.5 3.9 
Non-Hispanic origin 672 95.3 94.9 95.5 97.7 94.2 
Unknown 13 1.8 1.4 2.1 1.9 1.9 
Household Income 
less than $1,000 96 13.6 15.2 12.7 14.5 13.2 
$1,000 to $5,000 48 6.8 8.3 5.9 4.2 8.0 
$5,000 to $20,000 462 65.5 65.6 65.3 66.8 65.2 
more than $20,000 91 12.9 10.9 14.3 14.0 12.2 
unknown 8 1.1 0.0 1.9 0.5 1.4 
Household Occupancy 
Living Alone 326 46.2 52.5 42.0 48.6 45.6 
Living with Others 378 53.6 47.5 57.7 51.4 54.2 
unknown 1 0.1 0.0 0.2 0.0 0.2 
Federal Poverty Level 
100% Federal Poverty 397 56.3 57.6 55.2 53.7 57.7 
> 100% Federal 
Poverty 307 43.5 42.4 44.6 46.3 42.1 
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unknown 1 0.1 0.0 0.2 0.0 0.2 
Breast Cancer History 
No History 676 95.9 94.9 96.5 96.7 95.5 
Prior Diagnosis 29 4.1 5.1 3.5 3.3 4.5 
Final Diagnosis 
DCIS - Stage 0 138 19.6 29.3 13.4 19.2 19.8 
Invasive Breast Cancer 551 78.2 69.2 83.8 79.4 77.5 
LCIS - Stage 0 16 2.3 1.4 2.8 1.4 2.7 
Age  
Women below age 40 19 2.7 1.4 3.5 3.3 2.5 
Women Ages 40-50 224 31.8 29.0 33.8 32.7 31.1 
Women over Age 50 462 65.5 69.6 62.7 64.0 66.4 
Screening to Diagnosis Interval 
< 30 Days 426 60.4 0.0 100.0 59.8 60.8 
> 30 days 276 39.1 100.0 0.0 39.3 39.0 
Unknown 3 0.4 0.0 0.0 0.9 0.2 
Diagnosis to Treatment Interval 
< 30 Days 485 68.8 68.5 69.2 0.0 100.0 
> 30 days 214 30.4 30.4 30.0 100.0 0.0 
unknown 6 0.9 1.1 0.7 0.0 0.0 
Tumor Stage 
AJCC Stage I 127 18.0 21.0 16.0 14.5 19.8 
AJCC Stage II 226 32.1 31.2 32.9 36.9 30.1 
AJCC Stage III 115 16.3 10.1 20.2 15.9 16.5 
AJCC Stage IV 45 6.4 2.9 8.7 6.5 6.4 
Summary Distant 4 0.6 0.0 0.9 0.5 0.6 
Summary Local 1 0.1 0.4 0.0 0.0 0.2 
Summary Regional 4 0.6 0.4 0.7 0.5 0.6 
Unknown 12 1.7 1.8 1.4 2.3 0.8 
Unstaged 14 2.0 1.4 2.3 2.3 1.9 
Missing 157 22.3 30.8 16.9 20.6 23.1 
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Table 2. Prevalence of screening to diagnosis & diagnosis to treatment delays 
Variable 
Total 
(N) 
s-d 
delay 
(N) 
Prev 
(%) 95%CI 
d-t 
delay 
(N) 
Prev 
(%) 95%CI 
Region 
Northwestern 113 37 32.7 24.09 41.40 40 35.4 26.58 44.22 
Northern 38 18 47.4 31.49 63.24 4 10.5 0.77 20.28 
Southwestern 224 86 38.4 32.02 44.76 67 29.9 23.91 35.91 
Central 51 21 41.2 27.67 54.68 18 35.3 22.18 48.41 
Eastern 260 112 43.1 37.06 49.10 75 28.8 23.34 34.35 
Race 
White 404 150 37.1 32.42 41.84 127 31.4 26.91 35.96 
Black 256 102 39.8 33.85 45.84 82 32.0 26.32 37.75 
Asian 19 11 57.9 35.69 80.10 4 21.1 2.72 39.38 
American Indian 3 2 66.7 13.32 120.01 0 0.0 0.00 0.00 
Other 11 6 54.5 25.12 83.97 0 0.0 0.00 0.00 
Ethnicity 
Hispanic origin 20 10 50.0 28.09 71.91 1 5.0 -4.55 14.55 
Non-Hispanic origin 672 262 39.0 35.30 42.68 209 31.1 27.60 34.60 
Household Income 
less than $1,000 96 42 43.8 33.83 53.67 31 32.3 22.94 41.65 
$1,000 to $5,000 48 23 47.9 33.78 62.05 9 18.8 7.71 29.79 
$5,000 to $20,000 462 181 39.2 34.73 43.63 143 31.0 26.74 35.17 
more than $20,000 91 30 33.0 23.31 42.63 30 33.0 23.31 42.63 
Household Occupancy 
Living Alone 326 145 44.5 39.08 49.87 104 31.9 26.84 36.96 
Living with Others 378 131 34.7 29.86 39.45 110 29.1 24.52 33.68 
Federal Poverty Level 
100% Federal Poverty 397 159 40.1 35.23 44.87 115 29.0 24.51 33.43 
> 100% Federal Poverty 307 117 38.1 32.68 43.54 99 32.2 27.02 37.48 
Breast Cancer History 
No History 676 262 38.8 35.08 42.43 207 30.6 27.15 34.10 
Prior Diagnosis 29 14 48.3 30.09 66.46 7 24.1 8.56 39.71 
Final Diagnosis 
DCIS - Stage 0 138 81 58.7 50.48 66.91 41 29.7 22.09 37.33 
Invasive Breast Cancer 551 191 34.7 30.69 38.64 170 30.9 27.00 34.71 
LCIS - Stage 0 16 4 25.0 3.78 46.22 3 18.8 -0.38 37.88 
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Age  
Women below age 40 19 4 21.1 2.72 39.38 7 36.8 15.15 58.53 
Women Ages 40-50 224 80 35.7 29.44 41.99 70 31.3 25.18 37.32 
Women above Age 50 462 192 41.6 37.06 46.05 137 29.7 25.49 33.82 
Screening to Diagnosis Interval 
< 30 Days 426 0 0.0 0.00 0.00 128 30.0 25.69 34.40 
> 30 days 276 276 100.0 100.00 100.00 84 30.4 25.01 35.86 
Diagnosis to Treatment Interval 
< 30 Days 485 189 39.0 34.63 43.31 0 0.0 0.00 0.00 
> 30 days 214 84 39.3 32.71 45.79 214 100.0 100.00 100.00 
Tumor Stage 
AJCC Stage I 127 58 45.7 37.01 54.33 31 24.4 16.94 31.88 
AJCC Stage II 226 86 38.1 31.72 44.38 79 35.0 28.74 41.17 
AJCC Stage III 115 28 24.3 16.50 32.19 34 29.6 21.22 37.91 
AJCC Stage IV 45 8 17.8 6.61 28.95 14 31.1 17.58 44.64 
Summary Distant 4 0 0.0 0.00 0.00 1 25.0 -17.44 67.44 
Summary Local 1 1 100.0 100.00 100.00 0 0.0 0.00 0.00 
Summary Regional 4 1 25.0 -17.44 67.44 1 25.0 -17.44 67.44 
Unstaged 14 4 28.6 4.91 52.24 5 35.7 10.61 60.81 
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Table 3. Breast Cancer Screening to Diagnosis Delays Odds Ratios 
Variable 
s-d 
delay 
% 
Total 
(N) POR 95%CI 
Region 
Northwestern 32.7 113 1.00   
Northern 47.4 38 1.83 0.87 3.86 
Southwestern 38.4 224 1.27 0.79 2.04 
Central 41.2 51 1.43 0.72 2.82 
Eastern 43.1 260 1.50 0.95 2.38 
Race 
White 37.1 404 1.00   
Black 39.8 256 1.09 0.79 1.50 
Other 57.6 33 2.28 1.11 4.67 
Ethnicity 
Hispanic origin 50.0 20 1.57 0.65 3.83 
Non-Hispanic origin 39.0 672 1.00   
Household Income 
less than $1,000 43.8 96 1.57 0.87 2.84 
$1,000 to $5,000 47.9 48 1.85 0.91 3.78 
$5,000 to $20,000 39.2 462 1.28 0.80 2.06 
more than $20,000 33.0 91 1.00   
Household Occupancy 
Living Alone 44.5 326 1.49 1.10 3.02 
Living with Others 34.7 378 1.00   
Federal Poverty Level 
100% Federal Poverty 40.1 397 1.06 0.78 1.44 
> 100% Federal Poverty 38.1 307 1.00   
Breast Cancer History 
No History 38.8 676 1.00   
Prior Diagnosis 48.3 29 1.48 0.71 3.12 
Final Diagnosis 
DCIS - Stage 0 58.7 138 1.00   
Invasive Breast Cancer 34.7 551 0.37 0.25 0.54 
LCIS - Stage 0 25.0 16 0.24 0.08 0.77 
Age  
Women below age 40 21.1 19 0.50 0.16 1.50 
Women Ages 40-50 35.7 224 1.00   
Women above Age 50 41.6 462 1.26 0.90 1.74 
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Diagnosis to Treatment Interval 
< 30 Days 39.0 485 1.00   
> 30 days 39.3 214 0.99 0.72 1.38 
Tumor Stage 
AJCC Stage I 45.7 127 1.00   
AJCC Stage II 38.1 226 0.75 0.48 1.16 
AJCC Stage III 24.3 115 0.39 0.22 0.67 
AJCC Stage IV 17.8 45 0.28 0.12 0.62 
Summary Distant 0.0 4 0.06 0.00 1.81 
Summary Local 100.0 1 >999.99 <0.01 >999.99 
Summary Regional 25.0 4 0.41 0.04 3.92 
Unstaged 28.6 14 0.49 0.15 1.63 
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Table 4. Breast Cancer Diagnosis to Treatment Delays Odds Ratios 
Variable 
d-t 
delay 
% 
Total 
(N) POR 95%CI 
Region 
Northwestern 35.4 113 3.77 1.42 10.00 
Northern 10.5 38 1.00   
Southwestern 29.9 224 2.95 1.15 7.55 
Central 35.3 51 3.85 1.33 11.14 
Eastern 28.8 260 2.78 1.09 7.08 
Race 
White 31.4 404 1.00   
Black 32.0 256 1.03 0.74 1.43 
Other 12.5 32 0.29 0.11 0.79 
Ethnicity 
Hispanic origin 5.0 20 0.21 0.05 0.81 
Non-Hispanic origin 31.1 672 1.00   
Household Income 
less than $1,000 32.3 96 1.01 0.55 1.85 
$1,000 to $5,000 18.8 48 0.53 0.23 1.20 
$5,000 to $20,000 31.0 462 0.96 0.59 1.55 
more than $20,000 33.0 91 1.00   
Household Occupancy 
Living Alone 31.9 326 1.18 0.85 1.62 
Living with Others 29.1 378 1.00   
Federal Poverty Level 
100% Federal Poverty 29.0 397 0.88 0.64 1.22 
> 100% Federal Poverty 32.2 307 1.00   
Breast Cancer History 
No History 30.6 676 1.00   
Prior Diagnosis 24.1 29 0.76 0.33 1.76 
Final Diagnosis 
DCIS - Stage 0 29.7 138 1.00   
Invasive Breast Cancer 30.9 551 1.05 0.70 1.57 
LCIS - Stage 0 18.8 16 0.59 0.17 2.04 
Age  
Women below age 40 36.8 19 1.33 0.51 3.49 
Women Ages 40-50 31.3 224 1.00   
Women above Age 50 29.7 462 0.95 0.67 1.34 
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Diagnosis to Treatment Interval 
< 30 Days 30.0 426 1.00   
> 30 days 30.4 276 1.01 0.73 1.39 
Tumor Stage 
AJCC Stage I 24.4 127 1.00   
AJCC Stage II 35.0 226 1.60 0.99 2.58 
AJCC Stage III 29.6 115 1.24 0.71 2.17 
AJCC Stage IV 31.1 45 1.37 0.66 2.86 
Summary Distant 25.0 4 1.03 0.11 9.66 
Summary Local 0.0 1 0.19 <0.001 80.76 
Summary Regional 25.0 4 1.03 0.11 9.66 
Unstaged 35.7 14 1.67 0.53 5.30 
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Table 5. Adjusted Odds Ratio of Screening to Diagnosis Delays 
Variable 
Total 
(N) 
s-d 
delay 
% 
Adjusted 
  POR 95%CI 
Region 
Northwestern 37 32.7 1.00   
Northern 18 47.4 1.19 0.47 3.02 
Southwestern 86 38.4 1.45 0.88 2.39 
Central 21 41.2 1.58 0.75 3.30 
Eastern 112 43.1 1.62 0.97 2.73 
Race 
White 150 37.1 1.00   
Black 102 39.8 0.92 0.63 1.36 
Other 19 57.6 2.52 1.03 6.17 
Ethnicity 
Hispanic origin 10 50.0 1.36 0.44 4.19 
Non-Hispanic origin 262 39.0 1.00   
Household Income 
less than $1,000 42 43.8 1.01 0.49 2.08 
$1,000 to $5,000 23 47.9 1.08 0.47 2.47 
$5,000 to $20,000 181 39.2 0.92 0.53 1.60 
more than $20,000 30 33.0 1.00   
Household Occupancy 
Living Alone 145 44.5 1.35 0.93 1.97 
Living with Others 131 34.7 1.00   
Final Diagnosis 
DCIS - Stage 0 81 58.7 1.00   
Invasive Breast Cancer 191 34.7 0.40 0.27 0.59 
LCIS - Stage 0 4 25.0 0.24 0.07 0.81 
Age 
Women below age 40 4 21.1 0.30 0.08 1.14 
Women Ages 40-50 80 35.7 1.00   
Women above Age 50 192 41.6 1.34 0.94 1.92 
Diagnosis to Treatment Interval 
< 30 Days 189 39.0 1.00   
> 30 days 84 39.3 1.11 0.78 1.58 
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Table 6. Adjusted Odds Ratio of Diagnosis to Treatment Delays 
Variable 
Total 
(N) 
d-t    
delay 
% 
Adjusted 
  POR 95%CI 
Region 
Northwestern 40 35.4 3.07 0.87 10.88 
Northern 4 10.5 1.00   
Southwestern 67 29.9 2.39 0.69 8.33 
Central 18 35.3 2.97 0.78 11.25 
Eastern 75 28.8 2.08 0.60 7.18 
Race 
White 127 31.4 1.00   
Black 82 32.0 1.03 0.69 1.55 
Other 4 12.5 0.52 0.15 1.79 
Ethnicity 
Hispanic origin 1 5.0 0.23 0.03 1.97 
Non-Hispanic origin 209 31.1 1.00   
Household Income 
less than $1,000 31 32.3 0.94 0.45 1.97 
$1,000 to $5,000 9 18.8 0.43 0.17 1.09 
$5,000 to $20,000 143 31.0 0.89 0.51 1.56 
more than $20,000 30 33.0 1.00   
Household Occupancy 
Living Alone 104 31.9 1.39 0.94 2.07 
Living with Others 110 29.1 1.00   
Final Diagnosis 
DCIS - Stage 0 41 29.7 1.00   
Invasive Breast Cancer 170 30.9 0.93 0.60 1.43 
LCIS - Stage 0 3 18.8 0.52 0.14 1.98 
Age 
Women below age 40 7 36.8 2.28 0.76 6.82 
Women Ages 40-50 70 31.3 1.00   
Women above Age 50 137 29.7 0.91 0.62 1.33 
Diagnosis to Treatment Interval 
< 30 Days 128 30.0 1.00   
> 30 days 84 30.4 1.10 0.77 1.57 
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